The decision of which agent to add to metformin therapy should be made in collaboration with the person with diabetes and in accordance with their needs
The convergence argument tells you why someone designed the blend
These medications may also have implications for breast cancer care
Heres a breakdown of who may qualify for each medication (again for Ozempic this will be an off-label use): Adults with a BMI of 30 or higher or Adults with a BMI of 27 or higher and at least one weight-related condition, such as high blood pressure or high cholesterol
While it is highly effective for treating obesity and type 2 diabetes, it has a drawback: being peptide-based (made of short protein fragments), it is easily broken down in the body, making oral administration difficult and requiring injection
The peptides and athletic performance relationship is well documented, and maintaining activity during the starting period supports better outcomes long term